Pharmaceutical Cannabis and The Influence From Big Pharma

Grassroots Marketing discusses Pharmaceutical Cannabis and The Influence From Big Pharma with Michael Sassano, CEO of Somai Pharmaceuticals . Michael is the CEO and Chairman of the Board for Somai Pharmaceuticals LTD, a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Taking with him the product development knowledge honed in the competitive American market, Somai is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Michael has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Michael stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Michaels' primary goal for Somai is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.